Escient Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2018-05-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.escientpharma.com
Clinical Trials
9
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
An Open-Label Phase 1 Study in Healthy Male Subjects to Investigate the Absorption, Metabolism and Excretion of [14C]-EP262 Following Single-Dose Oral Administration
- First Posted Date
- 2024-10-17
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Escient Pharmaceuticals, Inc
- Target Recruit Count
- 10
- Registration Number
- NCT06645704
- Locations
- 🇺🇸
Pharmaron Clinical Pharmacology Center (CPC), Baltimore, Maryland, United States
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Oral EP262Drug: Placebo
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Escient Pharmaceuticals, Inc
- Target Recruit Count
- 30
- Registration Number
- NCT06144424
- Locations
- 🇺🇸
Allervie Clinical Research, Birmingham, Alabama, United States
🇺🇸RM Medical Research, Inc., Miami Lakes, Florida, United States
🇺🇸Indiana Clinical Trials Center, Plainfield, Indiana, United States
Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Drug: Oral EP262Drug: Placebo
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Escient Pharmaceuticals, Inc
- Target Recruit Count
- 113
- Registration Number
- NCT06077773
- Locations
- 🇺🇸
AllerVie Clinical Research, Birmingham, Alabama, United States
🇺🇸Scottsdale Clinical Trials, Scottsdale, Arizona, United States
🇺🇸Little Rock Allergy & Asthma Clinical Research Center, Little Rock, Arkansas, United States
Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria
- Conditions
- Chronic Inducible Urticaria
- Interventions
- Drug: Oral EP262
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Escient Pharmaceuticals, Inc
- Target Recruit Count
- 30
- Registration Number
- NCT06050928
- Locations
- 🇺🇸
Advanced Clinical Research Institute, Tampa, Florida, United States
🇺🇸Treasure Valley Medical Research, Boise, Idaho, United States
🇺🇸Allergy & Asthma Specialists, P.S.C., Owensboro, Kentucky, United States
Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Escient Pharmaceuticals, Inc
- Target Recruit Count
- 62
- Registration Number
- NCT05525520
- Locations
- 🇺🇸
University of Alabama Birmingham Hospital, Birmingham, Alabama, United States
🇺🇸Dignity Health Center for Clinical Research at St. Joseph Hospital, Phoenix, Arizona, United States
🇺🇸Southern California Research Center, Coronado, California, United States
- Prev
- 1
- 2
- Next